BioCryst Pharmaceuticals (MEX:BCRX) Cyclically Adjusted Revenue per Share: MXN23.61 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BCRX BioCryst Pharmaceuticals Inc MEX:BCRX
56 GF Score
Price MXN182.00
GF Value MXN218.09
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share?

BioCryst Pharmaceuticals MEX:BCRX 56 Cyclically Adjusted Revenue per Share is MXN23.61 as of Mar. 2026. GuruFocus rates MEX:BCRX with a GF Score™ of 56/100 and a GF Value™ of MXN218.09 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was MXN11.643. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN23.61 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioCryst Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 35.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 31.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 27.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioCryst Pharmaceuticals was 42.90% per year. The lowest was -23.20% per year. And the median was 3.75% per year.

As of today (2026-07-15), BioCryst Pharmaceuticals's current stock price is MXN182.00. BioCryst Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN23.61. BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 7.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioCryst Pharmaceuticals was 45.08. The lowest was 2.65. And the median was 8.64.


BioCryst Pharmaceuticals  (MEX:BCRX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=182.00/23.61
=7.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioCryst Pharmaceuticals was 45.08. The lowest was 2.65. And the median was 8.64.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.10 10.30 13.31 18.76 25.56

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.25 22.48 22.49 25.56 23.61

MEX:BCRX vs SUPN, PBH, AMLX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


MEX:BCRX
56GF Score
BioCryst Pharmaceuticals Inc MEX:BCRX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioCryst Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=11.643/330.2130*330.2130
=11.643

Current CPI (Mar. 2026) = 330.2130.

BioCryst Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.201 241.018 1.645
201609 2.036 241.428 2.785
201612 2.511 241.432 3.434
201703 2.364 243.801 3.202
201706 0.697 244.955 0.940
201709 1.902 246.819 2.545
201712 0.775 246.524 1.038
201803 0.733 249.554 0.970
201806 2.485 251.989 3.256
201809 0.258 252.439 0.337
201812 0.488 251.233 0.641
201903 1.037 254.202 1.347
201906 0.252 256.143 0.325
201909 0.317 256.759 0.408
201912 5.698 256.974 7.322
202003 0.734 258.115 0.939
202006 0.410 257.797 0.525
202009 0.764 260.280 0.969
202012 0.452 260.474 0.573
202103 2.197 264.877 2.739
202106 5.583 271.696 6.785
202109 4.706 274.310 5.665
202112 5.319 278.802 6.300
202203 5.376 287.504 6.175
202206 7.103 296.311 7.916
202209 8.192 296.808 9.114
202212 8.296 296.797 9.230
202303 6.576 301.836 7.194
202306 7.478 305.109 8.093
202309 7.967 307.789 8.547
202312 7.868 306.746 8.470
202403 7.471 312.332 7.899
202406 9.703 314.175 10.198
202409 11.143 315.301 11.670
202412 13.228 315.605 13.840
202503 13.831 319.799 14.281
202506 13.988 322.561 14.320
202509 13.298 324.800 13.520
202512 33.384 324.054 34.018
202603 11.643 330.213 11.643

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN23.61 mean?
BioCryst Pharmaceuticals (MEX:BCRX) has a Cyclically Adjusted Revenue per Share of MXN23.61 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
BioCryst Pharmaceuticals' current Cyclically Adjusted Revenue per Share is MXN23.61. Overall, BioCryst Pharmaceuticals has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to SUPN and PBH?
BioCryst Pharmaceuticals' Cyclically Adjusted Revenue per Share of MXN23.61 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Cyclically Adjusted Revenue per Share is MXN23.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (MEX:BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN218.09, compared to a current price of MXN182.00 — trading 16.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN23.61. BioCryst Pharmaceuticals' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioCryst Pharmaceuticals (MEX:BCRX), the current Cyclically Adjusted Revenue per Share is MXN23.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (MEX:BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of MXN182.00 is trading 16.5% below its estimated GF Value™ of MXN218.09. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:BCRX:

  • Cyclically Adjusted Revenue per Share: MXN23.61
  • GF Value™: MXN218.09 vs. price of MXN182.00 (16.5% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the MEX:BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:USABO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
56GF Score

Get the complete analysis for MEX:BCRX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN182.00
Price
MXN218.09
GF Value